Stock Price Quote

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

NSE : BIOFILCHEMBSE : 524396ISIN CODE : INE829A01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE53.64-2.34 (-4.18 %)
PREV CLOSE ( ) 55.98
OPEN PRICE ( ) 55.63
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1319
TODAY'S LOW / HIGH ( )53.61 55.67
52 WK LOW / HIGH ( )53.61 92
NSE53.83-2.81 (-4.96 %)
PREV CLOSE( ) 56.64
OPEN PRICE ( ) 56.64
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 41429
TODAY'S LOW / HIGH( ) 53.66 56.65
52 WK LOW / HIGH ( )53.55 91.87
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1985
Management Info
Ramesh Shah - Chairman Ramesh Shah - Managing Director
Registered Office

Address 11/12, Sector E,Sanwer Road,Industrial Area,
Indore,
Madhya Pradesh-452015

Phone 0731-2723016

Email bcplcompliance@gmail.com

Website www.biofilgroup.net

Registrars Details
Ankit Consultancy Pvt Ltd
Plot No 60,Electronic Complex,Pardeshipura,Indore
Listing : BSE, NSE

NEWS

03Apr Biofil Chemicals & Pharmaceuticals inf
Biofil Chemicals & Pharmaceuticals has informed that it attached Cer..
12Mar Biofil Chemicals & Pharmaceuticals inf
Biofil Chemicals & Pharmaceuticals has informed that the Exchange ha..
01Nov Biofil Chemicals & Pharmaceuticals sub
Biofil Chemicals & Pharmaceuticals has informed that the meeting of..
02Sep Biofil Chemicals & Pharmaceuticals inf
Biofil Chemicals & Pharmaceuticals has informed that it enclosed the..
24Aug Biofil Chemicals And Pharmaceuticals i
In terms of Regulation 47 of the SEBI (Listing Obligation and Disclosure..

Financials

in Millions
QTR Sep 24 ANNUAL 24
Net Profit0.2400000000000067.08999999999994
Gross Profit 0.320000000000006 8.64999999999995
Operating Profit 1.4000000000000113.0599999999999
Net Sales 24.13400.35

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE)
peergroup  7043.70 (1.90%)
M.Cap ( in Cr)17609.25
Kwality Pharma (BSE)
peergroup  991.15 (2.14%)
M.Cap ( in Cr)1028.44
Shree Ganesh Remed. (BSE)
peergroup  701.15 (2.95%)
M.Cap ( in Cr)900.11
Piramal Pharma (BSE)
peergroup  232.45 (4.87%)
M.Cap ( in Cr)30817.02
Gufic Biosciences (BSE)
peergroup  475.90 (2.08%)
M.Cap ( in Cr)4772.21

Shareholding Pattern

NON-INSTITUTION 53.1%
PROMOTERS 46.82%
FI/BANKS/INSURANCE 0.08%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%
FII 0%

About Biofil Chemicals & Pharmaceuticals Ltd.

Biofil Chemicals & Pharmaceuticals Ltd. was incorporated in the year 1985. Its today's share price is 53.64. Its current market capitalisation stands at Rs 87.29 Cr. In the latest quarter, company has reported Gross Sales of Rs. 400.35 Cr and Total Income of Rs.405.25 Cr. The company's management includes Meet Shah, Gayatri Padiyar, Satish Beohar, Ashok Kumar Ramawat, Ketan Shah, Ramesh Shah, Ramesh Shah.

It is listed on the BSE with a BSE Code of 524396 , NSE with an NSE Symbol of BIOFILCHEM and ISIN of INE829A01014. It's Registered office is at 11/12, Sector E,Sanwer Road,Industrial AreaIndore-452015, Madhya Pradesh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Maheshwari & Gupta, SN Gadiya & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.